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A monoclonal antibody to the gpl20-CD4 complex has differential effects
on HIV-induced syncytium formation and viral infectivity
Krystyna Konopka, 1 Elizabeth Pretzer, l Franco Celada z and Nejat Diizgiine~ ~'3.
1Department of Microbiology, University of the Pacific, School of Dentistry, San Francisco, CA 94115, ~Institute ..for
Molecular Immunology, Hospital for Joint Diseases, New York University, New York, N Y 10003 and 3Department of
Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143, USA

A murine monoclonal antibody (MAb F-91-55) raised
against the complex of soluble CD4 and human
immunodeficiency virus type 1 (HIV-1) gpl20 had
previously been found to inhibit syncytium formation
without inhibiting the interaction of CD4 with gpl20,
and its binding site was localized within the first two
domains (D 1/D2) of CD4. We investigated whether this
antibody inhibited the infectivity of HIV-1 in the CD4 +
T cell lines A3.01, Sup-T1 and H9. We also examined
the effect of the antibody on syncytium formation
between these cells and chronically infected H9 cells.
Syncytium formation was found to depend critically on
the incubation medium used. The effect of the MAb on
HIV-1 infectivity was very limited with A3.01 and Sup-

TI cells, although it inhibited syncytium formation
between A3.01 or Sup-T1 and chronically infected H9
cells. In contrast, the MAb inhibited significantly the
infectivity of HIV-1 in H9 cells, but it also inhibited
syncytium formation between H9 and chronically infected H9 cells to a greater extent than in the case of the
other cell lines. Our results indicate that cellular systems
used for syncytium assays differ in their susceptibility to
inhibitory antibodies. In the A3.01 and Sup-T1 cell
systems, the differences in the ability of the MAb to
block viral entry or syncytium formation raise the
possibility that the mechanisms of interaction of gp 120/
gp41 with cell membrane CD4 may be different in
cell-cell and virus-cell membrane fusion.

Introduction

Although the mechanisms of virus-cell and cell--cell
fusion are generally presumed to be similar, recent
studies have indicated that there are significant differences between them (Callebaut et al., 1994; Camerini &
Seed, 1990; Kalter et al., 1991 ; Pantaleo et al., 1991 a, b;
Sato et al., 1992).
The high-affinity binding site for gpl20 on CD4 has
been identified by mutagenesis, antibody-blocking and
crystallographic techniques as comprising the complementarity determining region 2 (CDR2)-like region and
supporting fl-strands of the D 1 domain of CD4 (reviewed
in Klasse et aI., 1993). Antibodies to this region block
gpl20 and virus binding to CD4 + cells, HIV infectivity of
CD4 + cells and HIV-1 mediated syncytium formation
(McDougal et al., 1986; Sodroski et al., 1986; Peterson
& Seed, 1988). In addition to acting as a receptor for
virus binding, CD4 may also be involved in the
subsequent membrane fusion step (Camerini & Seed,
1990; Hasanuma et al., 1992; Poulin et al., 1991 ; Truneh
et al., 1991). The CDR3-1ike region of CD4 (amino acids
81-102) (Sattentau et al., 1989) is thought to be involved
in HIV-mediated, CD4-dependent membrane fusion,
independent of its role in binding to gpl20 (Choe &
Sodroski, 1992; Lifson et al., 1988; Ohki et al., 1990;

Human immunodeficiency virus type 1 (HIV-1) predominantly utilizes the T cell surface antigen CD4 as a
receptor for infection of susceptible cells (reviewed in
Levy, 1993). Both the fusion of the viral and target CD4 +
cell membranes and the fusion of HIV-infected cells with
CD4 + cells is a pH-independent process, and is preceded
by the binding of the viral envelope glycoprotein gpl20
to CD4 (Lifson et al., 1986; Sodroski et al., 1986;
Sinangil et al., 1988; Stein & Engleman, 1991; Levy,
1993). The mechanism of this fusion reaction is an area
of active investigation. Binding of gpl20 to CD4 is
thought to induce conformational changes in both
molecules (Moore et al., 1991 ; Sattentau & Moore, 1991 ;
Eiden & Lifson, 1992) resulting in the interaction of the
fusion domain at the N terminus of gp41 with the target
cell membrane, leading to membrane fusion and the
release of the viral nucleocapsid into the cytosol.
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Rausch et al., 1992; Camerini & Seed, 1990). Certain
monoclonal antibodies (MAbs) directed against the nongpl20 binding epitopes of CD4 were reported to block
HIV infection and syncytium formation essentially
without inhibiting CD4-gpl20 binding. These include a
MAb (L71) to the CDR3-1oop (Truneh et al., 1991), a
MAb to the pre-CDR3-related region, amino acid
residues 72-84 (Ohki et al., 1992), a MAb (5A8) to the
D2 domain (Burkly et al., 1992; Moore et al., 1992) and
MAbs (Q425, Q428) to the D3 domain (Healey et al.,
1990). In contrast, some CD4 monoclonal antibodies
have differing effects on HIV entry and cell-cell fusion.
For example, an anti-CDR3 MAb, 13B8-2, inhibits both
recombinant gpl20 binding to cell surface CD4 (or
sCD4) and HIV-induced cell-cell fusion, but not the
binding of viral particles to cell-surface CD4 or virus
entry into CD4 + cells (Corbeau et al., 1993). MAbs (5D4,
7C2) to the D 3 / D 4 domains of CD4 inhibit HIV-1
infection but have no effect on CD4-gpl20 binding and
HIV-l-induced syncytium formation (Hasanuma et al.,
1992).
Another antibody raised against the complex of
soluble CD4 and gpl20 blocks syncytium formation
between CEM cells chronically infected with H1V-lm~
(or HIV-1Rv) and uninfected Molt 4 cells, without
inhibiting the interaction of CD4 with gpl20 (Celada et
al., 1990). The binding site of MAb F-91-55 (MAb 55)
has been localized within the first two domains (D 1/D2)
of CD4. The antibody exhibits greater binding to the
gpl20 complex of CD4 than to CD4 itself, suggesting
that it recognizes a gpl20-dependent conformational
change in CD4. However, whether the antibody also
inhibits viral infectivity has not been investigated (Celada
et al., 1990). Nevertheless, it has been assumed that MAb
55 inhibits viral infectivity as well as syncytium formation
(Moore et at., 1992; Gershoni et at., 1993; Golding et al.,
1993; Klasse et al., 1993). In view of the differential
effects of several antibodies on these two processes, we
have examined the ability of MAb 55 to inhibit HIV-1
infection of the CD4 + T cell lines A3.01, Sup-T1 and H9,
as well as its effect on syncytium formation between these
three cell lines and chronically HIV-1-infected H9 cells.
Methods
Compounds and antibodies. Murine monoclonal antibody (MAb F91-55, referred to as MAb 55), was raised in mice immunized with the
soluble CD4-gpl20 complex, as described by Celada et al. (1990), and
was used either as a purified MAb or ascites fluid containing the MAb
(ascites-55). Mouse immunoglobulin IgG1 was obtained from BectonDickinson; recombinant sCD4 was provided by Genentech. Phosphatebuffered saline containing 0.1 g/1 CaClo, 0.1 g/l MgC12.6H~O, 0.2 g/1
KCI, 0.2 g/1KH~PO 4, 8.0g/1NaC1 and 2.16 g/1Na~HPO~.7H~O,
designated PBS, was obtained from the UCSF Cell Culture Facility.
Phosphate-buffered saline containing 10 mM-sodium/potassium phosphate and 0-9 % NaC1, designated PBS Ca,Mg-free or PBS (CMF), was

prepared from packets obtained from Zymed Laboratories and filtersterilized.
Cells and viruses. A3.01 cells were obtained from T. Folks (Centers
for Disease Control, Atlanta, Georgia, USA). Sup-T1 cells from J.
Hoxie and H9 cells from R. C. Gallo were provided by the AIDS
Research and Reference Reagent Program (Division of AIDS, NIAID,
NIH, Bethesda, Maryland, USA). H9/HTLV-IIIB cells were kindly
provided by J. Mills (San Francisco General Hospital). H9 cells
infected with HIV-IIIIB, at 4 ng viral p24 per 1 x 106 cells, m.o.i. =
0-0002, were designated as H9/HIV-l~IIB and used 31 days postinfection. Viral p24 antigen was determined in cell-free supernatant by
the antigen capture assay as described previously (Konopka et al.,
1990). All cell lines were maintained at 37 °C, under 5% CO 2 in
Medium A consisting of RPMI 1640 medium (lrvine Scientific)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS), penicillin (50 units/ml), streptomycin (50/ag/ml) and L-glutamine (2 mM). The cells were split 1 : 6 and fresh medium was added
every 3 to 4 days. HIV-1 LAy LA~(formerly the LAV-BRU strain) (WainHobson et al., 1991), initially provided by F. Barr6-Sinoussi (Pasteur
Institute, Paris, France), was propagated in human lymphoblastoid
leukemia (CEM) cells, and purified as described by Larsen et al. (1990)
and stored at - 7 0 °C. The purified HIV-1 was propagated in A3.01
cells and designated HIV-1 m~u. The supernatant of chronically infected
H 9 / H T L V - I I I B cells was used as a source of the HIV-1 strain HIVlmR. The culture supernatants were harvested at times of peak p24
production, filtered through Millipore filters of 0.22 gm pore diameter,
and stored in 1 ml aliquots at - 8 0 ° C . The reverse transcriptase
activity of the virus stock solutions was 2-5x 10s and 3.9x
10k c.p.m./ml for HIV-1Br~u and HIV-IIIIB, respectively, as detected by
the method of Hoffman et al. (1985). The ELISA-reactive p24 protein
yielded 2-6 gg/ml for H1V-I~R v and 0-3 ~tg/ml for HIV-lms.
The tissue culture infectious dose, 50 % endpoint (TCIDs0), was
determined as described by Johnson & Byington (1990). The infectious
titre per 100 ng p24 antigen was 4.6 x 105 TCIDs0 (both on A3.01 and
H9 cells) for HIV-1BR~, and 4"8 x 10~ TCIDs0 (on H9 cells) for HIVAssays for CD4-dependent HIV-l-hlduced cell fusion. Syncytium
formation was evaluated by inverted phase contrast microscopy at
25 × magnification, as described by Lifson (1993). After 16-20 h of cocultivation, syncytium formation had proceeded to its full extent and
cell fusion was typically extensive enough to warrant a 3 + score. A
score of 4+ was assigned to numerous large syncytia with a low
number of viable cells and 5 + to numerous syncytia and no viable
cells. Diluents alone served as a neutral control; sCD4, known to block
HIV-l-induced syncytium formation, served as a positive control for
inhibition of cell fusion. Since sCD4 inhibits a process different from
that inhibited by MAb55, the sCD4 concentration dependence of the
inhibition of syncytia was not determined in our studies.
H I V infection of cells. Ceils (2 × 107/ml) were exposed to HIV-1 for
2 h at 37 °C, washed three times to remove unbound virus, resuspended
at 0.5 × 106 or 1 x 106 cells/ml in Medium A and cultured in 24-well
culture plates (2 ml per well). Viral inocula were standardized by their
p24 content and cultures were infected at a concentration of 2 or 4 ng
p24 per 1 x 106 cells. Where indicated, cells were infected in the presence
of MAb 55, then washed three times and cultivated further in the absence
of antibody. The MAb 55 was present onh, during the initial exposure
of cells to the virus, therefore, the level of p24 antigen determined in
the culture medium several days later is a measure of the effect of the
antibody on the initial infection by cell-free virus, i.e. virus-cell fusion.
Since the cells were infected at a very low m.o.i, and subsequently
washed~ the measured p24 values reflect de novo viral replication, and
not any input virus. Control cells were treated similarly but not exposed
to the virus. Every 2, 3 or 4 days, 1 ml of the supernatant was removed
and fresh medium was added, p24 antigen in the harvested medium was

H I V infectivity vs syncytia formation
measured by ELISA (Konopka et al., 1990). Cell viability was assessed
visually both with and without the use of trypan blue. The viability of
the cellswas determined before each experiment, and only cultures with
> 98 % viability were used. In the infectivityexperiments, viability was
determined at times of p24 determination and ascertained to be
comparable to controls.

hibition was observed at a 1 : 100 dilution of ascites-55 in
serum-free medium, while significant cell-cell fusion
occurred in complete medium. Although syncytium
formation was less efficient in PBS (CMF) (score 3 + )
than in PBS (4 + ) , the inhibitory activity of ascites-55
was comparable (Fig. 1). In contrast, syncytium formation between H 9 / H T L V - I I I B and H9 cells was very
ineffÉcient (data not shown). However, the more recently
developed H9/HIV-I~H ~ cells were capable of forming
syncytia with H9 cells at an efficiency comparable to that
with Sup-T1 cells in complete medium (score 5 + ) , and at
a somewhat lower efficiency in serum-free medium (score
3 + ) (Fig. 2). Syncytium formation between H9 and
H 9 / H I V - I , ~ B cells was more sensitive to the inhibitory
effect of M A b than that between Sup-T1 and H 9 / H T L V IIIB cells (Figs 3, 4a and 5a). Interestingly, fusion
between H9 and H 9 / H I V - l m B cells was also more
sensitive to the assay conditions than was fusion between
H 9 / H T L V - I I I B and A3.01 or Sup-T1 cells. F o r example,
the efficiency of syncytium formation in the presence of
PBS (score + ) or PBS (CMF) (score ± ) was very low
(Fig. 2).

Detection of CD4. The presenceof cell surface CD4 was examined by
direct immunofluorescence assay, using fluorescein isothiocyanate
(FITC)-conjugated Leu3 antibody (Becton-Dickinson), with FITCconjugated mouse IgG as a control. The fluorescencedistribution was
analysed with a fluorescence-activatedcell sorter (FACScan; BectonDickinson).

Results
Inhibition of HIV-l-induced syncytium formation by
MAb 55
We investigated the effect of M A b 55 on syncytium
formation between chronically infected H 9 / H T L V - I I I B
or H 9 / H I V - 1 H m cells and three uninfected CD4 + T cell
lines, A3.01, Sup-T1 and H9. The relative efficacy of
purified M A b and ascites-55 was compared in parallel
experiments with Sup-T1 and A3.01 cells (Table 1). Both
purified M A b and ascites-55 substantially inhibited
syncytium formation, while no inhibitory effect was
found for mouse IgG1 at 10 lag/ml. Complete inhibition
was observed with purified M A b at 10 ~tg/ml and ascites
at 1:200 or 1 : 100 dilution, with both cell lines. Sup-T1
cells were less sensitive to the anti-fusion effect of M A b
than A3.01 cells; for example, at 1 lag M A b / m l or 1:500
dilution of ascites-55, complete inhibition of syncytium
formation was observed with A3.01 cells while some
cell-cell fusion occurred with Sup-T1 cells (Table 1).
To characterize the inhibitory effect of M A b 55 on
cell--cell fusion under the conditions used in the infectivity studies, we performed the assay in complete or
serum-free medium and compared that with results
obtained in PBS and PBS (CMF). H 9 / H T L V - I I I B cells
formed syncytia with Sup-T1 cells under all these
conditions (Fig. 1). Ascites-55 blocked syncytium formation to a much higher extent in serum-free than in
complete medium. F o r example, almost complete in-

The effect of MAb 55 on HIV-1 infectivity depends on
the cell type
We examined whether the inhibitory effect of M A b 55 on
HIV-mediated cell-cell fusion was also exerted on
virus-cell fusion. A3.01, Sup-T1 or H9 cells were infected
with HIV-1BRv or HIV-I~Im in the absence or presence of
purified M A b 55 or ascites-55. FACS analysis indicated
that 92 %, 98 % and 60 % of A3.01, Sup-T1 and H9 cells,
respectively, were CD4-positive. The background-subtracted mean fluorescence was 100, 140 and 40 (arbitrary
units), for A3.01, Sup-T1 and H9 cells, respectively.
Surprisingly, in view of the dramatic inhibition of
syncytia formation discussed above, the effect of M A b
on HIV-1 infectivity in A3.01 and Sup-T1 cells was very
limited. The antibody at 0.1 lag/ml did not affect viral
p24 production in A3.01 cells. When A3.01 cells were
infected in the presence of 1 lag M A b / m l , the production

Table 1. Syncytium formation in the presence of purified MAb F-91-55 and ascites

containing MAb-55*
Ascites-55 (dilution)

Purified MAb (ixg/ml)
Cell
type

0.1

1

10

Sup-T1
A3.01

+
_+

±
-

--

IgG 1
1:2000 1:1000 1:500 1:200 1:100 (10 lag/ml)
2+
+

+
±

_+
--

671

--

-

3+
3+

Control
3+
3+

* Syncytia were scored 16-20 h after the addition of chronically infected H9/HTLV-IIIB cells to uninfected
Sup-T1 or A3.01 cells. Appropriate dilutions of purified MAb 55 or ascites-55 were prepared in 200 lal PBS
(CMF). MAb remained in the assay during the co-incubation period.
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Sup-T1 cells
1:500 ascites-55

Control

RPMI +
10% FBS

RPMI
(serum-flee)

PBS

PBS (CMF)

Fig. I. Syncytiumformation between Sup-Tl and H9/HTLV-IIIB cells under different conditions in the absence or presenceof ascites55 at a dilution of l : 500.

of p24 antigen in the culture supernatant was inhibited
by 2 0 % and 14.3%, on days 3 and 7 post-infection,
respectively. At 10 ~tg/ml, the M A b reduced the infectivity of the virus by only 16%. The M A b inhibited
the infectivity of the virus in Sup-T1 cells to a greater

extent. The amount of p24 produced on day 3 was
reduced by 20%, 31.1% and 44.4% at 0"1, 1.0 and 10 ~tg
m A b / m l , respectively, and after 5 days the inhibition was
43-5 %, 34-6 % and 56.2 %, respectively. The presence of
mouse IgG1, at 10 gg/ml, during initial infection did not

HIV i~(ectivity vs syncytia formation
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H9 cells

1:500 ascites-55

Control

RPMI +
10% FBS

RPMI
(serum-free)

PBS

PBS (CMF)

Fig. 2. Syncytium formation between H9 and H9/HIV-1111B cells under different conditions in the absence or presence of ascites-55 at
a dilution of 1 : 500.

affect virus production appreciably when compared to
untreated A3.01 or Sup-T1 cells (data not shown).
We also determined virus production in A3.01 and
Sup-T1 cells exposed to HIV-1B~~ in the presence of

several dilutions of ascites-55. As with the purified MAb
55, ascites-55 reduced the p24 production with Sup-T1
cells to a greater extent than with A3.01 cells. For
example, at a 1:100 dilution of ascites-55, 20% and
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Sup-Tl cells

H9 cells

Control
(Complete
Medium A)

Ascites-55

1:500

5 2 ".;:'

4 *~:

1:200

[:100

Fig. 3. Syncytiumformation between Sup-T1 and H9/HTLV-IIIB or H9 and H9/HIV-I m~ cells in complete medium A in the absence
and presence of ascites-55, at dilutions of 1:500, 1:200 and 1: 100.

32"7 % inhibition of p24 production was observed with
A3.01 and Sup-T1 cells after 7 days, respectively.
Ascites-55 blocked syncytium formation between SupT1 and H 9 / H T L V - I I I B cells to a much higher extent in
serum-free than in complete medium (Fig. 1). To test

whether the absence of serum can increase the inhibitory
effect of M A b on HIV-1 infectivity, p24 production was
determined after the exposure of Sup-T1 cells to either
HIV-1B~ v or HIV-1HIB in serum-free medium. Under
these conditions ascites-55 did not inhibit de novo

HIV infectivity vs syncytia formation
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5
8

4

e..,
o

3
2

51
r/3

0.4

0.3
0.2
¢..q

0.1
0.0

Control 1:2000 1:1000 1:500 1:200 1:100
Ascites F-91-55

Fig, 4. Effect of ascites-55 on syncytium formation between Sup-T1 and H9/HTLV-IIIB (a) and HIV-1uiB replication in Sup-T1 cells
(b). (a) Appropriate dilutions of ascites-55 in 200 gl Of serum-freemedium were added to the wells containing uninfected Sup-T1 cells
and infected H9/HTLV-IIIB cells were added subsequently. After 16 h of co-cultivation in the continuous presence or absence of
antibodies, syncytium formation was scored (score 1+ = 1). (b) Sup-T1 cells were exposed to HIV-ImB at 2 ng p24 per l0 s cells (at
an m.o.i, of 0.0001) in serum-free medium in the presence of antibody as described in Methods. p24 antigen was determined in cell
culture supernatant on day 3 post-infection. Data represent the mean + standard deviation of p24 determinations in duplicate, in
supernatants of two replicate wells (n = 4) or triplicate wells (control infections) (n = 6)~

infection with either H I V - l m B or HIV-1BR~j (Fig. 4b and
data not shown). These results contrast sharply with the
significant inhibition of syncytium formation (Fig. 4a).
Substantial differences were observed in the sensitivity
of Sup-T1 and H9 cells to the inhibitory effect of M A b
on syncytium formation with infected cells (Fig. 3). To
test whether the infectivity of the virus might exhibit
similar differences, we investigated the effect of M A b 55
on HIV-1 infection of H9 cells. When H9 cells were
infected with HIV-1B~ v in the presence of 0.1 gg
M A b / m l in complete medium, virus production was
inhibited by 6 0 % and 36%, on days 7 and 10 postinfection, respectively. At 1 and 10 ~tg/ml, M A b 55
reduced p24 production by 83.3% and 85"7%, respectively, on day 10 post-infection. A significant
inhibitory effect was also observed when H9 cells were
infected with the HIV-1B~u isolate at a concentration of
13 ng p24 per 106 cells (m.o.i. = 0"06) in the presence of
ascites-55 in serum-free medium. Ascites-55, diluted
1 : 100, reduced p24 production by 73 % and 66.3 %, on
days 4 and 7 post-infection, respectively. The M A b

inhibited the infectivity of H I V - l m B in H9 cells to an
even greater extent (Fig. 5 b and data not shown). Virus
production was reduced by 87%, 9 1 % and 89%, on
days 10, 14 and 17 post-infection, respectively, with a
1:100 dilution of ascites-55. Thus, under the same
conditions, ascites-55 inhibited significantly the infectivity of H I V - l m B in H9 cells (Fig. 5b) without affecting
its infectivity in Sup-T1 cells (Fig. 4b).

Discussion
Our results on HIV-l-induced syncytium formation
demonstrate that (i) it is influenced by the composition of
the medium; (ii) significant differences exist a m o n g
various uninfected and infected T cells in supporting
cell-cell fusion; and (iii) the different T cell lines differ in
their sensitivity to the inhibitory effect of M A b on HIVinduced syncytium formation. The molecular factors in
the medium responsible for the different extents of
syncytium formation are not known. The difference in
the antibody sensitivity between the cell lines may be
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4

8

(a)

3

o

2

y.,

1

r~

0
3.0
2.5
2.0
21.5
~z~ 1.0

0-5
0.0

Control 1:2000 1:1000 1:500 1:200 1:100
Ascites F-91-55

Fig. 5. Effect of ascites-55 on syncytium formation between H9 and H9/HIV-lmB (a) and HIV-1IIIBreplication in H9 cells (b). (a)
Appropriate dilutions of ascites-55 in 200 ~tl of serum-freemedium were added to the wells containing uninfected H9 cells and infected
H9/HIV-1H,B cells were added subsequently. After 16 h of co-cultivation in the continuous presence or absence of antibodies,
syncytium formation was scored (score 1+ = 1). (b) H9 cellswere exposed to HIV-I,~Bat 4 ng p24 per 106cells (at an m.o.i, of 00002),
in serum-freemedium in the presence of antibody as described in Methods. p24 antigen was determined in cell culture supernatant on
day 10 post-infection.Data represent the mean -4-standard deviation of p24 determinations in duplicate, in supernatants of two replicate
wells (n = 4) or triplicate wells (control infections) (n = 6),

related to the difference in the intrinsic susceptibility of
the cells to HIV-induced fusion. F o r example, H9 cells
appear to be less prone to extensive syncytium formation
compared to Sup-T1 cells, and the inhibition of cell-cell
fusion by M A b 55 in this system is more pronounced.
The lower syncytium-supporting ability of H9 cells
observed here may be due to the lower level of CD4
expression on the cells compared to Sup-T1 cells, the
lower percentage of CD4 + cells in the cultures, and
perhaps the lower fusogenic efficiency of H9 cells
independent of the CD4 level (Lu et al., 1992). K a b a t et
al. (1994) have found that the level of CD4 present on the
surface of susceptible CD4 + cells is not the sole
determinant of virus entry or syncytium formation. The
differences in syncytium formation observed under the
different environmental conditions utilized in our studies
are in agreement with the observation that Ca 2+ are
required for HIV-induced cell fusion but not for binding
of sCD4 to gpl20/gp41-expressing cells (Dimitrov et al.,
1993). Our observation that various T cells differ in their
ability to support HIV-induced syncytium formation

under different conditions suggest that the 'fusogenic
properties' of both uninfected CD4 + and infected cells
influence syncytium formation. F o r example, De Jong et
al. (1992) reported that A3.01 cells do not support
syncytium formation, despite a high level of viral
replication, while in our studies A3.01 cells could easily
form syncytia with chronically infected H9 cells.
While our results on three different cell lines have
confirmed previous observations that M A b 55 inhibits
syncytium formation (Celada et al., 1990), they indicate
that the antibody is not particularly inhibitory to H I V
infectivity in Sup-T1 and A3.01 cells. This M A b is
thought to prevent a post-binding event necessary for
membrane fusion without inhibiting the interaction of
CD4 with gpl20. One question raised by our findings is
why virus-cell fusion should be less affected by the antibody than cell-cell fusion in the A3.01 and Sup-T1 cell
systems. It has been reported that a mutation (517A) in
the N terminus of HIV-1 gp41 markedly affects cytopathicity, with only minimal effects on virus replication
(Kowalski et al., 1991). Similarly, virus entry is

H I V infectivity vs syncvtia f o r m a t i o n

disrupted less than syncytium formation by changes in
HIV-1 gp41 residues 566 to 596 (Cao et al., 1993).
Mutations in the N terminus of HIV-2 gp41 which
increase the charge and the polarity and/or decrease the
hydrophobicity of the fusion domain severely reduce the
capacity of the virus to induce syncytia, but only slightly
affect virus infectivity (Steffy et al., 1992). It is also
possible that viral gp120/gp41 can interact more effectively than cellular gpl20/gp41 with accessory molecules
in the cell membrane that may be involved in the
membrane fusion reaction. Syncytium formation does
not occur in LFA-1- CD4 + T lymphocytes despite
efficient HIV infection (Pantaleo et al., 1991a, b). In
addition, HIV-1 isolates differ in their capacity to induce
syncytia in vitro (Tersmette et al., 1989). Clearly, assays
for syncytia formation should not be used as sole
indicators of HIV infection.
Another question raised by our findings is why MAb
55 inhibits HIV-1 infection in H9 cells more effectively
than in A3.01 or Sup-T1 cells. One possibility is that
the interaction of HIV-1 with H9 cell membranes leading
to virus-cell membrane fusion and nucleocapsid delivery
into the cytoplasm has more stringent molecular
requirements than its interaction with Sup-T1 cells.
Thus, MAb 55 can more readily interfere with the proper
orientation or alignment of HIV-I envelope and cell
surface molecules necessary for the membrane fusion
reaction, subsequent to binding to CD4. Indeed, we have
found that the extent of viral nucleocapsid delivery into
H9 cells within 30 rain at 37 °C is 5'5-fold less than that
into Sup-T1 cells, although the extent of membrane lipid
mixing is comparable (L. Stamatatos, S. Nir & N.
Dtizgiine~, unpublished data). This observation suggests
that the membrane reorganization leading to complete
membrane fusion (with nucleocapsid delivery) is less
efficient in the case of H9 cells than Sup-Tl cells. Thus,
the presence of the antibody interferes effectively with an
already inefficient process in H9 cells, while it cannot
interfere with an efficient fusion reaction in the case of
Sup-T1 cells. Similarly, the cell type used markedly
affects the anti-HIV activity of polyanionic compounds
and glycosylation inhibitors (Schols et al., 1992).
Recently, Gershoni et al. (1993) have described several
MAbs against the CD4/gpl20 complex, some of which
inhibit cell-~zell fusion to different degrees; however,
their effect on HIV infection was not reported. Moore et
al. (1992) have shown that preincubation of sCD4 with
MAb 55 substantially reduces binding of sCD4 to HIVlniB-infected H9 cells and, as a result, inhibits sCD4induced gp120 shedding. In contrast, using recombinant
proteins, Celada et al. (1990) have shown that MAb 55
does not inhibit sCD4-gpl20 binding when all the
components are co-incubated. Thus, the results reported
by Moore et al. (1992) suggest that the formation of the

677

sCD4-MAb complex is necessary for the inhibition of
sCD4-gpl20 binding, and emphasize the importance of
the experimental conditions in the interaction of these
molecules.
Investigations on the regions of CD4 other than the
gp 120 binding site involved in HIV-1 envelope-mediated
membrane fusion have provided contradictory data
(Lifson et al., 1988; Camerini & Seed, 1990; Ohki et al.,
1990; Rausch et al., 1992; Corbeau et al., 1993; Broder
& Berger, 1993). The role of the anti-CDR3 MAb 13B82, specific for sequences surrounding amino acid 87, is
also controversial. According to Rey et al. (1991) and
Corbeau et al. (1993), MAb 13B8-2 blocks both the
binding of gpl20 to sCD4 and HIV-induced syncytium
formation, but has varying degrees of effect on virus
binding to cell-surface CD4 and HIV-1 infectivity. Our
observations that MAb 55 was more effective in blocking
syncytium formation than HIV-1 infectivity are in
general agreement with those of Rey et al. (1991) and
Corbeau et al. (1993) with MAb 13B8-2. Curiously,
Dalgleish et al. (1984) presented data (in their Table 3)
indicating that all the anti-CD4 MAbs they used
inhibited both HIV-l-induced syncytium formation and
pseudotype infection, while they noted in the text that
pseudotype inhibition was not always achieved with
some MAbs.
Interestingly, MAbs 5D4 and 7C2 to the D3/D4
domains of CD4 inhibit HIV-1 infection without
inhibiting HIV-1 induced syncytium formation (Hasanuma et al., 1992), thus exerting the opposite differential
effect compared to MAb 55. Similarly, the inhibition of
infection without impairment of virus binding and
syncytium formation was reported with a plant lectin,
jacalin, which binds to the carbohydrates located on the
D3/D4 domains of CD4 (Corbeau et al., 1994; Favero
et al., 1993). Thus, it becomes evident that although
both virus-cell and cell-cell fusion require the specific
interaction of gpl20/gp41 with CD4, there are other
characteristics of CD4, aside from its gpl20 binding,
which may play critical roles in post-binding events.
Our studies have been performed with laboratory
isolates of HIV-1. In view of the differences between such
strains and primary isolates with respect to syncytium
induction, tropism, CD4-dependence and susceptibility
to inhibition by sCD4 (Daar et al., 1990; Levy, 1993;
Kabat et al., 1994), it will be useful in future studies to
examine the effect of MAb 55 on infection of peripheral
blood mononuclear cells by primary isolates and on
syncytium formation in these cells. Finally, the observation of Benkirane et al. (1993) that the MAb 13B82 against the CDR3-1ike region of CD4 inhibits viral
replication in previously HIV-infected CEM cells leads
to the question of whether MAb 55 will have a similar
effect in the same or other infected cell lines.
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